Q2 Results Show Initial LYMPHIR Revenue, $21.5M Capital Secured to Extend Runway to November 2026

summarizeSummary

Citius Oncology reported Q2 fiscal 2026 results with initial LYMPHIR revenue and a large net loss, but secured $21.5 million in new capital, extending its cash runway to November 2026 and mitigating immediate going concern concerns.

check_boxKey Events

• Q2 Fiscal 2026 Financial Results

  Reported net revenue of $1.7 million for the quarter and $5.6 million for the first half of fiscal 2026 from the LYMPHIR launch. The net loss for the quarter was $26.6 million, significantly impacted by a $19.7 million one-time CMO contract cancellation charge.

• Liquidity and Going Concern Update

  Confirmed the receipt of $21.5 million in new capital from warrant exercises ($11.5M) and the first tranche of a senior secured term loan ($10M). This financing extends the company's cash runway to November 2026, addressing the immediate going concern risk previously noted for May 2026.

• LYMPHIR Commercial Progress

  Achieved strong market access with near 100% payer coverage and 83% of target accounts on formulary or in review. Initial European shipments have also commenced.

auto_awesomeAnalysis

Citius Oncology reported its fiscal second quarter 2026 results, showing initial net revenue of $1.7 million from its LYMPHIR launch, contributing to $5.6 million for the first half of the fiscal year. However, the company posted a significant net loss of $26.6 million for the quarter, primarily due to a one-time $19.7 million contract cancellation charge related to a CMO termination. Critically, the company updated its liquidity outlook, confirming the receipt of $21.5 million in new capital from warrant exercises and a senior secured term loan. This financing extends the company's cash runway from the previously stated May 2026 to November 2026, directly addressing the immediate going concern risk highlighted in prior filings.